In the long struggle to close the gap between what medicine can detect and what patients will actually submit to, Guardant Health has offered a quiet but significant answer: a blood test that identified 83 percent of colorectal cancers across 20,000 participants, measured against the colonoscopy standard. The result clears the FDA's minimum threshold for reimbursement eligibility and arrives at a moment when roughly 50 million Americans remain out of compliance with existing screening methods. It is not the perfect instrument, but it may be the accessible one — and in public health, accessibil
Guardant's blood test detects 83% of colorectal cancers in pivotal trial
A blood test removes the friction that keeps millions away from screening.
Mark
So the test caught 83 percent of cancers. Is that good enough?
Mimi
It clears the FDA's minimum threshold of 74 percent, and it's the first blood test to show this kind of sensitivity for colorectal cancer. But analysts had expected 85 to 86 percent, so it came in a bit short of what the market was betting on.
Luke
What about the false positives? The story mentions 10 percent of positive tests were ruled out by colonoscopy. That's not trivial.
Mimi
Right. So if you test positive, there's a meaningful chance you'll need a colonoscopy anyway to confirm. That's the trade-off—you avoid the test for 90 percent of people, but for the 10 percent who test positive, you're not eliminating the colonoscopy.
Mark
And the advanced adenomas—the precancerous growths—it only caught 13 percent of those?
Mimi
Yes. That's where it really underperformed expectations. Analysts thought it would catch 20 to 25 percent. That's a real limitation if the goal is to find and remove polyps before they become cancer.
Luke
But the FDA doesn't require a minimum sensitivity for adenomas, only for cancer itself. So that gap might not block approval.
Mark
What's the actual timeline here?
Mimi
Guardant says it'll submit to the FDA in early 2024 and hopes for approval in the very early part of that year. If that happens, the test could be available to patients within months.
Luke
And the market opportunity—50 million unscreened Americans—is that number solid?
Mimi
It comes from CDC data showing 70 percent of adults 50 to 75 are up-to-date with screening. The math on the remaining 30 percent checks out, but that assumes they're all eligible and willing to use a blood test instead of avoiding screening altogether.
Mark
So this could be genuinely transformative if it works as hoped.
Mimi
If it gets approved and insurers cover it, yes. The friction of colonoscopy and stool tests has kept millions away from screening. A blood test removes that barrier.
Le Pouls
- Colorectal cancer kills tens of thousands of Americans each year, yet half the eligible population avoids screening because existing methods — colonoscopies, stool tests — demand too much time, discomfort, or indignity.
- Guardant's trial results landed slightly below Wall Street's expectations of 85–86% sensitivity, sending a ripple of uncertainty through investor confidence even as the science itself clears the regulatory bar.
- The test's 13% detection rate for precancerous adenomas trails far behind colonoscopy and Cologuard, raising real questions about how much early-stage disease a blood draw alone can catch.
- Guardant's leadership is reframing the story: this is not a colonoscopy replacement but a friction-removal tool — a way to bring 50 million non-compliant Americans into the screening fold with nothing more than a blood draw.
- With an FDA submission planned for early 2024 and a reimbursement pathway already signaled by Medicare guidelines, the test could reach patients within months of approval — reshaping the landscape of routine cancer screening.
In the long struggle to close the gap between what medicine can detect and what patients will actually submit to, Guardant Health has offered a quiet but significant answer: a blood test that identified 83 percent of colorectal cancers across 20,000 participants, measured against the colonoscopy standard. The result clears the FDA's minimum threshold for reimbursement eligibility and arrives at a moment when roughly 50 million Americans remain out of compliance with existing screening methods. It is not the perfect instrument, but it may be the accessible one — and in public health, accessibility often matters more than perfection.
Guardant Health announced that its experimental blood test detected 83 percent of colorectal cancers in a 20,000-person trial, benchmarked against colonoscopy. The test also identified 13 percent of advanced adenomas — the precancerous growths that colonoscopy is specifically designed to catch. The company called it a landmark: the first demonstration that a simple blood draw can reliably detect colorectal cancer at scale.
The numbers fell just short of what analysts had anticipated — predictions had clustered around 85 to 86 percent sensitivity for cancer, and 20 to 25 percent for adenomas. But Guardant's co-CEO AmirAli Talasaz pushed back on that framing, arguing the results validate an entirely new approach to screening. The test also produced a 10 percent false-positive rate, meaning one in ten people who tested positive were cleared by follow-up colonoscopy — a figure that matters when designing a tool meant to screen millions.
The urgency behind the science is demographic. The CDC estimates that roughly 30 percent of adults aged 50 to 75 are not current with any colorectal cancer screening. That translates to approximately 50 million people — not because they are uninformed, but because the available options carry real friction. Colonoscopy requires sedation and lost work time. Cologuard, the leading stool-based test, detects 92 percent of cancers but many patients simply won't use it. A blood test eliminates nearly all of that resistance.
The regulatory path is already partially cleared. Medicare and Medicaid have indicated they will reimburse blood-based colorectal cancer tests that achieve at least 74 percent sensitivity and earn FDA approval — a bar Guardant's 83 percent clears. The company plans to submit its full data package to the FDA in early 2024, with approval potentially following shortly after.
Guardant is not moving through an empty field. Exact Sciences and Illumina's Grail unit are pursuing similar blood-based cancer detection technologies. Guardant itself is running a parallel trial for lung cancer. But if its colorectal test clears review on schedule, it could mark the moment a needle and a vial became the new front line of cancer prevention.
Guardant Health announced Thursday that its experimental blood test caught 83 percent of colorectal cancers in a trial of 20,000 people, measured against colonoscopy as the standard. The test also detected 13 percent of advanced adenomas—the precancerous growths that colonoscopy is designed to find and remove. The company is positioning this as a watershed moment: the first time a simple blood draw has shown it can reliably identify colorectal cancer at scale.
The results land slightly below what Wall Street analysts had wagered. Puneet Souda at SVB Securities had predicted the trial would show sensitivity around 85 to 86 percent for cancer and 20 to 25 percent for advanced adenomas. But AmirAli Talasaz, Guardant's co-chief executive, framed the outcome as validation of a fundamentally different approach to screening. "We are showing for the first time that a blood test can really detect colorectal cancer with high sensitivity," he said. The company also found that a follow-up colonoscopy ruled out cancer in 10 percent of people who initially tested positive on the blood test—a false-positive rate that matters for a screening tool meant to cast a wide net.
The stakes here are demographic and urgent. According to the CDC, only about 70 percent of adults aged 50 to 75 are current with colorectal cancer screening using any available method. That leaves roughly 50 million Americans who are not complying with existing tests. Talasaz called this "a huge unmet clinical need." The barrier is not ignorance; it is friction. Colonoscopy requires sedation and a day off work. Cologuard, a stool-based test marketed by Exact Sciences, identifies 92 percent of colorectal cancers and 42 percent of precancerous polyps—but many people find the test unpleasant enough to skip it. A blood test removes that friction almost entirely.
The FDA has already signaled what it will accept. Medicare and Medicaid Services guidelines state the agency will reimburse blood-based biomarker tests for colorectal cancer screening if they achieve at least 74 percent sensitivity and receive FDA approval. Guardant's 83 percent clears that bar. The company expects to submit its full data package to the FDA in early 2024 and is aiming for approval in the very early part of that year—a timeline that would make the test available to patients within months.
Guardant is not alone in this race. Exact Sciences and Illumina's Grail unit are also developing DNA blood tests for early-stage cancer detection. Guardant is simultaneously running a separate trial of its blood test for lung cancer, expanding the potential market for the technology. If the company clears FDA review as planned, it could reshape how millions of Americans approach cancer screening—replacing a procedure many avoid with a test that requires nothing more than a needle and a vial.
Citations marquantes
We are showing for the first time that a blood test can really detect colorectal cancer with high sensitivity.— AmirAli Talasaz, Guardant Health co-chief executive
There are still 50 million people out there who are not complying with colorectal cancer screening.— AmirAli Talasaz, Guardant Health co-chief executive
Envie de l'histoire complète ?
Lire l'original sur Devdiscourse ↗
Economy & Finance